determin
potenti
antivir
effect
ribavirin
ncov
isol
replic
suscept
cell
infect
follow
h
absorpt
infect
cell
treat
either
ribavirin
vero
cell
reduc
cytopathogen
effect
cpe
start
concentr
uml
complet
elimin
cpe
uml
figur
ribavirin
reduc
cpe
start
concentr
complet
elimin
cpe
figur
viral
protein
level
measur
nucleocapsid
protein
express
cell
lysat
also
reduc
presenc
increas
level
reduct
start
uml
figur
respons
ribavirin
treatment
reduct
nucleocapsid
protein
express
observ
appear
dose
depend
figur
supernat
collect
day
postinfect
subsequ
analys
viral
load
viral
rna
titer
perform
peak
viral
load
infecti
viru
recov
day
sampl
therefor
time
point
use
subsequ
analysi
supernat
collect
day
frequent
lower
viral
load
titer
sampl
collect
day
like
due
extens
cpe
day
sampl
includ
analys
dose
depend
reduct
genom
copi
observ
treatment
reduct
viral
load
uml
reach
reduct
uml
figur
dose
depend
reduct
viral
load
also
observ
ribavirin
treatment
reduct
reach
reduct
figur
importantli
correspond
decreas
infecti
viru
also
observ
result
ribavirin
treatment
reduct
viru
titer
occur
uml
increas
reduct
uml
figur
ribavirin
reduct
viru
titer
observ
reach
reduct
figur
inhibitori
concentr
ribavirin
subsequ
determin
uml
respect
tabl
reduct
reduct
valu
also
calcul
tabl
signific
find
concentr
ribavirin
requir
effect
inhibit
replic
quit
high
may
therefor
limit
clinic
applic
vero
cell
describ
compar
resist
ribavirin
ineffici
convert
ribavirin
mono
triphosph
therefor
also
assess
sensit
ribavirin
cell
figur
b
base
ic
valu
cell
respons
ribavirin
treatment
tabl
maximum
concentr
test
uml
reduc
infecti
titer
reduct
genom
copi
ribavirin
treatment
higher
reduc
infecti
viru
detect
threshold
given
long
histori
combin
use
treatment
hepat
combin
ribavirin
treatment
determin
whether
one
compound
would
augment
activ
combin
treatment
vero
cell
lower
threshold
decreas
cpe
note
vero
cell
reduc
uml
ribavirin
absenc
cpe
uml
ribavirin
figur
repres
decreas
amount
ribavirin
respect
requir
achiev
reduct
either
treatment
alon
viral
nucleocapsid
protein
express
also
reduc
dose
depend
manner
start
concentr
ribavirin
uml
respect
figur
reduct
cpe
nucleocapsid
protein
express
also
correl
reduc
viru
genom
copi
titer
administ
ribavirin
ratio
addit
reduct
viru
titer
treatment
alon
figur
ongo
identif
case
suggest
continu
introduct
viru
human
middl
east
unknown
sourc
given
genet
relationship
bat
one
specul
bat
may
reservoir
viru
howev
addit
host
speci
consid
document
humantohuman
transmiss
close
contact
situat
first
document
mild
real
concern
could
observ
tip
iceberg
perhap
start
epidem
regardless
casefat
rate
despit
intens
medic
intervent
therapeut
strategi
urgent
need
despit
signific
increas
research
coronavirus
sinc
discoveri
sarscov
definit
antivir
therapeut
treatment
coronaviru
infect
human
pegyl
shown
effect
prophylact
treatment
infect
sarscov
cynomolgu
macaqu
less
effect
administ
post
therapeut
test
antivir
activ
sarscov
higher
order
anim
model
sarscov
mous
model
poli
ic
adenoviru
express
mous
protect
mice
lethal
diseas
howev
neither
approach
yield
immedi
therapeut
use
human
poli
ic
lc
test
numer
clinic
trial
current
approv
treatment
human
diseas
adenovirusbas
therapi
multipl
complic
factor
preexist
immun
adequ
address
approv
use
identifi
potenti
therapeut
approach
combin
ribavirin
either
treatment
alon
reduc
viru
replic
least
much
suscept
cell
line
moreov
combin
efficaci
reach
lower
concentr
thu
combin
may
provid
benefit
treatment
human
vero
cell
display
high
level
resist
activ
thu
also
perform
assay
cell
sensit
ribavirin
observ
much
lower
concentr
previou
vitro
studi
demonstr
sarscov
sensit
variou
class
interferon
sensit
sarscov
ribavirin
appear
cell
line
depend
concentr
low
ribavirin
report
unfortun
concentr
higher
peak
serum
concentr
reach
human
approxim
previous
report
inhibit
growth
sarscov
start
uml
reduct
follow
infect
iuml
shown
dose
depend
antivir
studi
report
nearli
reduct
viru
titer
compar
dose
outbreak
sarscov
differ
combin
therapeut
intervent
attempt
howev
none
implement
manner
allow
critic
assess
effect
frequent
administ
therapeut
broadspectrum
antibiot
glucocorticoid
lack
standard
dose
regimen
ribavirin
make
comparison
howev
low
dose
ribavirin
mgday
therapi
shown
ineffect
like
due
insuffici
plasma
contrast
use
higher
dose
studi
found
ribavirin
alon
reduc
viral
load
half
patient
combin
viral
proteas
inhibitor
lopinavirritonavir
patient
lower
incid
advers
despit
use
larg
number
patient
still
remain
unclear
whether
ribavirin
alon
effect
synthet
also
suggest
benefici
unfortun
studi
suffer
confound
use
corticosteroid
dose
vari
among
studi
make
definit
treatment
elus
suggest
combin
interferon
ribavirin
treatment
ribavirin
result
revers
hemolyt
anemia
complic
typic
occur
follow
longer
treatment
suggest
shortcours
ribavirin
therapi
acut
infect
ncov
may
signific
complic
mild
anemia
frequent
report
side
effect
ribavirin
treatment
lassa
viru
synergist
effect
ribavirin
previous
report
vitro
felin
infecti
periton
howev
observ
addit
effect
studi
level
ribavirin
requir
inhibit
ncov
replic
must
achiev
human
order
relev
clinic
use
human
interferon
concentr
iuml
observ
intraven
inject
ribavirin
achiev
follow
mg
intraven
ribavirin
alon
shown
antivir
effect
howev
vero
cell
concentr
requir
achiev
benefici
effect
like
higher
achiev
human
combin
inhibitori
concentr
ribavirin
drop
rang
like
achiev
human
suggest
combin
potenti
treatment
option
use
earli
cours
infect
given
prophylact
close
contact
sick
individu
close
contact
transmiss
document
infect
chain
combin
may
improv
clinic
outcom
addit
reduc
viral
load
would
also
like
translat
reduc
viru
shed
thu
reduc
risk
secondari
transmiss
two
drug
current
use
togeth
clinic
combin
therapi
includ
ribavirin
consid
case
patient
manag
new
ncov
case
possibl
prophylaxi
highli
expos
individu
infecti
work
perform
high
contain
facil
rocki
mountain
laboratori
rml
divis
intramur
research
dir
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
work
approv
rml
institut
biosafeti
committe
ibc
biosafeti
level
human
betacoronaviru
emc
kindli
provid
erasmu
medic
center
rotterdam
netherland
vero
african
green
monkey
kidney
rhesu
monkey
kidney
maintain
dulbecco
modifi
eagl
media
dmem
supplement
fetal
bovin
serum
fb
uml
penicillin
streptomycin
hcovemc
subsequ
propag
vero
cell
use
dmem
fb
complet
dmem
confluent
vero
cell
cultur
plate
costar
corn
ny
infect
triplic
dilut
complet
dmem
moi
follow
h
adsorpt
inoculum
remov
cell
wash
time
dmem
subsequ
complet
dmem
contain
uml
pbl
interferon
sourc
piscataway
nj
andor
ribavirin
mp
biomed
solon
oh
ad
cell
cell
incub
h
humidifi
environ
supernat
remov
aliquot
inactiv
avl
qiagen
germantown
md
viral
load
quantif
remaind
store
subsequ
viru
titrat
supernat
replac
fresh
complet
dmem
contain
andor
ribavirin
supernat
also
collect
h
h
five
day
postinfect
repres
well
photograph
document
cytopath
effect
cpe
cell
subsequ
collect
protein
analysi
sdspage
load
buffer
rna
avltreat
supernat
extract
nucleospin
viru
core
kit
machereynagel
bethlehem
pa
corbett
xtractor
gene
valencia
ca
quantit
real
time
rtpcr
use
primer
probe
previous
perform
rotorgen
q
qiagen
dilut
seri
viral
rna
base
equival
use
standard
cell
lysat
run
sdspage
gel
transfer
pvdf
ge
healthcar
piscataway
nj
membran
block
nonfat
milk
pb
subsequ
probe
polyclon
serum
dilut
block
buffer
rabbit
immun
inactiv
hcovemc
antirabbit
igg
conjug
horseradish
peroxidas
kpl
gaithersburg
md
use
secondari
dilut
western
blot
develop
pierc
ecl
plu
kit
thermo
rockford
il
confluent
vero
cell
infect
triplic
dilut
supernat
obtain
antivir
assay
viru
allow
adsorb
h
remov
replac
complet
dmem
cell
incub
humidifi
environ
day
cpe
score
tissu
cultur
infecti
dose
calcul
describ
reed
data
genom
quantif
assay
analyz
prism
graphpad
softwar
compusyn
combosyncom
conceiv
design
experi
df
hf
perform
experi
df
edw
cm
jc
analyz
data
df
edw
vjm
hf
contribut
essenti
reagent
vjm
wrote
manuscript
df
edw
vjm
hf
author
review
manuscript
